Kornimate/medical-research-clean huggingface dataset:
glucose monitoring in youth with cystic fibrosis during pulmonary exacerbations

Conditions: Cystic Fibrosis Pulmonary Exacerbation

Summary: the goal of this study is to investigate the prevalence of dysglycemia with continuous glucose monitoring (cgm) obtained during pulmonary exacerbations, both outpatient and inpatient, in youth with cystic fibrosis (cf).

this research is using continuous glucose monitoring (cgm) to study changes in blood sugar levels that may occur in youth with cystic fibrosis (cf) and cystic fibrosis related diabetes (cfrd) who experience a pulmonary exacerbation (pex), whether admitted to the hospital or seen in clinic. we hypothesize that 1) youth experiencing a pex will have greater blood sugar changes during the pex than at least 6 weeks after the pex , 2) that the changes in blood sugars will be greater during the pex when compared to cgm data gathered at a baseline visit prior to the pex (when available), 3) and that blood sugar changes during the pex will compare with changes in short-term clinical outcomes collected using questionnaires about breathing problems, and that this data will be predictive of the need for additional antibiotics. this study aims to compare cgm measures of change during a pex with those measured after recovery; to compare cgm measures of change during the pex to those taken at baseline; and to examine the relationships between these changes and the changes in clinical findings including the need for additional antibiotics.

Eligibility criteria:
inclusion criteria: * 6- 25 years old * confirmed diagnosis of cystic fibrosis (based on sweat chloride and/or two known disease causing cf mutations) * access to a smart phone and/or internet connection and the ability to complete remote telehealth visits exclusion criteria: * known type 1 or type 2 diabetes, monogenic diabetes * critical illness requiring admission to the icu * pregnancy

Keywords: cystic fibrosis related diabetes continuous glucose monitoring cystic fibrosis pulmonary exacerbation
post photorefractive keratectomy (prk) use of an eye shield for maintaining vision and mitigating pain

Conditions: Pain; Vision Nearsighted

Summary: the purpose of this research is to determine if an investigational thin shield over the cornea can safely and effectively reduce or eliminate pain following post photorefractive keratectomy (prk). the thin shield is made of silicone. the materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.

see above

Eligibility criteria:
inclusion criteria. * subjects age 18 and older with healthy eyes. * nearsightedness between -0.50 diopters and -11.00 diopters with or without astigmatism of up to 3.50 diopters. exclusion criteria. * subjects under the age of 18. * patients with excessively thin corneas. * patients with topographic evidence of keratoconus. * patients with ectactic eye disorders. * patients with autoimmune diseases. * patients who are pregnant or nursing. * any other anterior segment abnormality other than that associated with prk * any abnormalities associated with the eye lids * uncontrolled blepharitis or dry eye * prior laser treatment of the retina * any ophthalmic surgery performed within three (3) months prior to study excluding prk or lasik * diagnosis of glaucoma * active diabetic retinopathy * clinically significant inflammation or infection within six (6) months prior to study * uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of the investigator * participation in any study involving an investigational drug within the past 30 calendar days, or ongoing participation in a study with an investigational material * intolerance or hypersensitivity to topical anesthetics, antibiotics, steroids or any other pharmaceuticals that may be used pre and post surgically specifically known intolerance or hypersensitivity to contact lenses or any component of the investigative material * a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up * any condition that, in the opinion of the investigator, would jeopardize the safety of the patient

Keywords: corneal shield prk myopia pain vision
study evaluating safety and tolerability of ascending multiple dose of slv-313 in schizophrenia patients

Conditions: Healthy

Summary: randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.


Eligibility criteria:
inclusion criteria: * men, aged 18-50 years old * women, aged 18-50 years old exclusion criteria: * non-lactating women, aged 18-50 years old * non-pregnant women, aged 18-50 years old

Keywords: safety,tolerability, schizophrenia
systemic erythropoietin injection in patients having optic atrophy

Conditions: Optic Atrophy

Summary: the purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

the purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. the intervention is systemic erythropoietin injections (eprax 10000 iu subcutaneous twice daily for three days). follow up after one month and three months by recording visual acuity and electro physiological studies.

Eligibility criteria:
inclusion criteria: * post papilledemic optic atrophy patients exclusion criteria: * refuse to give an informed consent
&#34;salivary melatonin and cortisol levels in individuals with bruxism&#34;

Conditions: Bruxism

Summary: the effects of the hormones melatonin and cortisol, which play a highly effective role in regulating the sleep-wake cycle, on teeth grinding will be scientifically evaluated. based on the research results, more effective methods for treating patients suffering from bruxism may be identified.


Eligibility criteria:
inclusion criteria: - individuals without any known hormonal diseases, not using antidepressants or medications that could alter saliva content, without degenerative diseases affecting the salivary glands, without cysts or tumors affecting the temporomandibular region, and not undergoing insomnia treatment will be included in the study exclusion criteria: * individuals with systemic diseases that affect or may potentially affect saliva content, or those using medications that cause these effects, will not be included in the study

Keywords: melatonin saliva cortizol
hemodynamic monitoring with mixed venous saturation

Conditions: Critically Ill

Summary: in this study the investigators aim to evaluate the utility of a continuous mixed venous saturation monitoring compared to a clinical examination in a group of critically ill patients.

we will compare possible difference in terms of sensibility and specificity regarding the continuous mixed venous saturation monitoring compared to clinical examination in a group of critically ill patients.

Eligibility criteria:
inclusion criteria: * critically ill patients with a central venous catheter exclusion criteria: * patients with pulmonary catheter

Keywords: hemodynamic monitoring mixed venous saturation critically ill patients
an investigation of the relationship between temporomandibular disorder with posture and pedobarographic analysis

Conditions: Temporomandibular Disorder

Summary: the aim of the study is, to evaluate the whole body posture and plantar pressure distributions in individuals with temporomandibular disorder and also in people with healthy temporomandibular joints. a study group aged between 18-35 years, 30 patients, who were diagnosed with research diagnostic criteria for temporomandibular disorders (rdc/tmd) who applied us with jaw pain and 30 healthy people at the same age range as a control group were included in the study. both groups received global postural assessments by using posturescreen mobile® (psm) program which is using four side photographs and the new york posture scale (nyps). static pedobarographic measurements were taken.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of temporomandibular diseases * clinical diagnosis of healthy temporomandibular joint exclusion criteria: * trauma history * anatomic deformities and skeletal system fractures * orthopedic or rheumatic diseases diagnosed * pregnancy * having tmr treatment * being included in the physiotherapy program in the last 6 months

Keywords: plantar pressure distribution posture posturescreen mobile rdc/tmd tmd
personalized antiplatelet therapy in cad patients

Conditions: Coronary Artery Disease

Summary: this study is a prospective, no-randomized, single-center study performed on 15000 consecutive coronary artery patients from dec. 2016 to oct. 2021. all these patients were detected cyp2c19 genotype. the antiplatelet treatment was recorded according to the therapy actually adopted by the patients.


Eligibility criteria:
inclusion criteria: 1.aged \>18 years old; 2. coronary angiography confirmed that there was at least one coronary artery stenosis \>70%; or the degree of stenosis of the left main artery stenosis \>50%; 3. at least one clinical phenotype of coronary heart disease is present: stable angina or acute coronary syndrome 4.to be able to sign informed consent. exclusion criteria: 1. combined with severe valvular heart disease; 2. combined with severe congenital heart disease; 3. combined hyperthyroidism, anemia and other high-powered heart disease; 4. with pulmonary heart disease; 5. with hypertrophic obstructive cardiomyopathy; 6. severe hypotension (sbp \<90mmhg or dbp \<60mmhg at enrollment); 7. liver dysfunction (defined as alt or total bilirubin is greater than the normal upper limit of 3 times); 8. renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); 9. high-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases; 10. active peptic ulcer and skin ulcers; 11. a patient who is allergic to clopidogrel, ticagrelor, or aspirin; 12. patients with a history of cardiogenic shock within two weeks; 13. pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age; 14. in the past 3 months participated in other clinical researchers; 15. persons who do not have legal or legal competence; 16. any condition that the investigator considers unsuitable for participation in the clinical study.

Keywords: cyp2c19
analysis of biomarkers from patients with chorioretinal diseases

Conditions: Diabetic Retinopathy; Macular Degeneration

Summary: this study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

this prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. ocular biomarkers were analyzed.

Eligibility criteria:
inclusion criteria: * age over 20 years * patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity. * patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. * control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders. exclusion criteria: * under the age of 20 years * patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor * patients that did not signed the informed consent of the trial * patients with intraocular inflammations or infections that requiring any pharmaceutical agent * patients with recent ocular trauma
ralox as second line treatment for advanced malignant biliary system tumor

Conditions: Cholangioadenoma

Summary: the purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.

the purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor. single arm，phase ii study for patients with cholangiocarcinoma or gallbladder carcinoma after first line treatment failure to explore effection and safety of raltitrexed combined with oxaplatin as second line treatment；sample size：50.

Eligibility criteria:
inclusion criteria 1. 18-75 years old. 2. patients with unresectable advanced advanced gallbladder carcinoma or cholangiocarcinoma confirmed by histology or cytology. 3. first-line chemotherapy failure (toxic side effects can not be tolerated, disease progression during treatment or relapse after treatment) ;or the disease recurred within 6 months after completion of adjuvant chemotherapy. 4. at least one measurable lesion according to recist1.1 criteria. 5. ecog: 0 \~ 1. 6. life expectancy ≥ 12 weeks. 7. the major organs were functioning normally, and the laboratory examination results within 1 week met the following conditions before enrollment:①absolute neutrophil count (anc)≥1.5×109/l ②platelet count（plt）≥80.0 × 109/l ③hemoglobin concentration（hb） ≥90g/l④ total bilirubin（tb）≤1.5×uln ⑤ serum creatinine （cr）≤l.5×uln ，endogenous creatinine clearance \>60ml/min（cockcroft-gault formula ）⑥aspartate aminotransferase (ast), alanine aminotransferase (alt), alkaline phosphatase(ap): ≤3 ×uln (≤5 ×uln for metastases to liver). 8. sign the informed consent voluntarily. exclusion criteria 1. allergic to any research drug and its excipients. 2. prior use of raltitrexed or oxaliplatin. 3. history of other malignancies, except cured basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix. 4. there is a history of brain metastases. 5. history of psychotropic drug abuse and cannot quit or has a mental disorder. 6. uncontrolled chronic infectious and non-infectious diseases. 7. active or clinically poorly controlled severe infection 8. other conditions that the researchers think should be ruled out.

Keywords: cholangioadenoma first line treatment failure raltitrexed; oxaliplatin
efficacy and safety of 1565-nm non-ablative fractional laser versus long-pulsed 1064-nm nd:yag laser in the treatment of enlarged facial pores

Conditions: Enlarged Facial Pores

Summary: facial pores are visible openings of pilosebaceous follicles, it is one of the important factors that affect the appearance of facial skin. this study aims to evaluate and compare the efficacy and safety of 1565 nm non-ablative fractional laser (nafl) and long-pulsed 1064 nm nd:yag laser (lpny) in the treatment of enlarged facial pores.

facial pores are visible openings of pilosebaceous follicles. these openings are not fixed structures and they can be affected by many factors, including sebum secretion, skin elasticity, hair thickness, age, hormones and ultraviolet exposure. these enlarged pores remain a cosmetic problem that impacts patient quality of life. at present, there is no unified evaluation standard for enlarged facial pores, and the mechanisms that underline enlarged facial pores remain unclear. various methods have been used to treat enlarged facial pores mainly focus on the possible causes. treatment options include topical retinoic acid, oral isotretinoin, antiandrogen therapy, injections of botulinum toxin type a, chemical peeling, lasers, radiofrequency, and ultrasound devices. in recent years, various studies on laser treatments of facial pores are gradually increasing because of good efficacy and limited adverse reactions. the 1064-nm lpny has been widely used for facial rejuvenation. many studies have confirmed that lpny can reduce facial wrinkles and improve skin elasticity. some researchers have used it to treat enlarged pores, and it has shown good results. recently, 1565-nm nafl is introduced for skin resurfacing, it has also been shown to be effective in treating enlarged facial pores. however, there are not enough clinical researches to confirm their efficacy, and no study has compared these two laser treatments before. so this is the first self-comparative study to compare the safety and efficacy of two lasers in the treatment of enlarged facial pores.

Eligibility criteria:
inclusion criteria: * subjects with enlarged facial pores who were screened by a designated dermatologist exclusion criteria: * infectious skin disease or systemic disease; skin tumors; pregnancy and lactation; patients with a history of glucocorticoids, immunosuppressant drugs and other drugs within 4 weeks; a history of keloid; a medical history of chemical peelings, filler injections, plastic surgery, or laser therapy on the face in the last 3 months

Keywords: facial pores non-ablative fractional laser long-pulsed nd:yag laser
clinical validation of the point-of-care msd influenza test

Conditions: Influenza Human

Summary: the primary objective of this study is to evaluate the performance of the msd® influenza test in detecting influenza a and influenza b in subjects presenting with influenza-like-illness (ili).

this is a multicenter, prospective study to evaluate the performance of the msd influenza test for the detection and differentiation of influenza a (including a/h1, a/h3, and a/h5 subtypes) and influenza b. nasal swabs from subjects presenting at the clinical care facility with ili will be collected and tested on the msd influenza test. results from the test will be compared to results obtained from viral culture performed on a second nasal swab at a reference laboratory.

Eligibility criteria:
inclusion criteria: * any subject (all ages) presenting with ili (defined as fever \[subjective or documented\] and cough or sore throat), and suspected of having influenza. * subject (parent, guardian, or authorized legal representative) gives informed consent or assent (child) to the study, and provides signed authorization for use and disclosure of protected health information. exclusion criteria: * any subject classified as "high risk" for exposure to avian or novel influenza, as determined by a risk-assessment questionnaire. * subjects who had prior nasal wash/aspirate or nasopharyngeal wash/aspirate specimens collected for routine health-care purposes within the same suspected influenza infection episode.

Keywords: influenza infections orthomyxoviridae infections
nutritional programme for dementia elderly patient

Conditions: Alzheimer's Disease; Dementia

Summary: the main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme. the secondary objectives are the improvement of the state of nutrition, a reduction in the use of resources and a reduction in the burden on the main carer.

main objective the main objective of this project is the evaluation of the effectiveness of a nutrition programme in patients with alzheimer's or other dementias. through the nutrition programme the idea is to reduce functional and weight loss in elderly people with cognitive deterioration and their families. evaluation of the effectiveness of the intervention -the main evaluation criteria which will allow the effectiveness of this intervention to be evaluated are the reduction in the loss of autonomy measured by the da/ida scale. secondary objectives the secondary objectives of this study are: * improvement in the patient's state of nutrition the measurement criteria which will allow the patient's nutritional state to be evaluated will be their weight, bmi and mna. * reducing the burden on carers. the zarit scale will be used for this evaluation. * evaluation of the use of healthcare and social resources. the rud scale will be used. * improvement of medical practice regarding nutrition. * evaluation of the representatives of our population with regard to the participation in a programme of these characteristics evaluating. * evaluation of the satisfaction of elderly people and their families in relation to the programme.

Eligibility criteria:
inclusion criteria: * the patient has dementia according to dsm iv criteria. * the patient has an mmse less than or equal to 26. * the patient lives in his/her home. * the patient is in the charge of a carer. * informed consent for participation in the study by the responsible relative and, if possible, from the patient or legal guardian. exclusion criteria: * the patient lives in an institution. * the patient is in a terminal situation. * the patient does not have a main carer. * patient has a nasogastric feed.

Keywords: alzheimer disease dementia elderly nutrition malnutrition weight loss
work ability-productivity among clinical health workers endometriosis study

Conditions: Endometriosis

Summary: a qualitative multicentre study protocol. the prospective research explores clinical health workers with a diagnosis of endometriosis, experiencing regular pain and their perceptions of work ability-productivity.

endometriosis has a significant impact on women at work physically, psychologically, and socially. notably, pain is the most common reported concern, and considerably reduces work ability and productivity. however, previous research has principally focused on general workers, discounting the varied nature of work roles. health workers appear to have an increased occupational risk of developing the condition, when compared with other shift workers and the general working population. taking these findings into account, the prospective work aches study explores the relationship between clinical health workers' regular endometriosis pain, and their perceptions of work ability-productivity during such events. this multicentre qualitative study will invite employees with a diagnosis of endometriosis and working in clinical settings, to participate in the study. recruitment will be carried out through study posters displayed in staff areas and occupational health departments, as well as snowballing methods. semi-structured interviews will take place via microsoft teams to discuss participants' experiences of endometriosis pain at work and their work ability-productivity while symptomatic. thematic analysis will be performed to interpret the data. the study has sought ethical approval from birkbeck university of london's ethics committee, the integrated research application system and the health research authority. following the completion of the study, a summary of findings will be shared with participants and agreed hospitals. the full study report will also be disseminated to all parties involved and accessed through the university of london's library thesis collection and published in relevant specialty journals.

Eligibility criteria:
inclusion criteria: * women aged between 18-65 years. * employed working within a clinical setting health role. * english speaking. * currently working full or part time hours. * diagnosis of endometriosis (as reported by participant, as medical records will not be accessed for the purpose of this study). * experiences regular endometriosis associated pain. exclusion criteria: * painful comorbidities. * unemployed women. * pregnant women.

Keywords: work ability work productivity pain clinical health workers nurses doctors